Hormone Replacement Therapy

Primary Care - Clinics in Office Practice

Volumn 33, Issue 4, 2006, Pages 953-963

  Dull, Pamela ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CIMICIFUGA RACEMOSA EXTRACT; CLONIDINE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DROSPIRENONE PLUS ESTRADIOL; ESTRADIOL; ESTRADIOL PLUS LEVONORGESTREL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; FEMRING; FLUOXETINE; GABAPENTIN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PAROXETINE; PHYTOESTROGEN; PIPERAZINE ESTRONE SULFATE; PLACEBO; TESTOSTERONE; VENLAFAXINE;

ALTERNATIVE MEDICINE; ANGELICA SINENSIS; BLOOD PRESSURE; BOTANY; BREAST CANCER; BREAST TENDERNESS; CANCER RISK; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DIET SUPPLEMENTATION; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPAREUNIA; ESTROGEN THERAPY; GYNECOLOGY; HEALTH CARE ORGANIZATION; HEALTH HAZARD; HIP FRACTURE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; LIVER FUNCTION; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; MENOPAUSE; OBSTETRICS; OFF LABEL DRUG USE; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN IRRITATION; SOYBEAN; STROKE; TRANSDERMAL PATCH; TREATMENT DURATION; TREATMENT WITHDRAWAL; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA RING; VAGINAL DRYNESS; WOMEN'S HEALTH;

AGED; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; PRACTICE GUIDELINES; SOCIETIES, MEDICAL; UNITED STATES; WOMEN'S HEALTH;

EID: 33845351708     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2006.09.008     Document Type: Review

References (42)

1. NIH State-of-the-Science Panel. National Institutes of Health state-of-the-science conference statement: management of menopause-related symptoms. Ann Intern Med 142 12 (2005) (Part 1):1003-13
2. Rossouw J.E., Anderson G.L., Prentice R.L., et al., for the Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
3. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (2002) 49-57
4. Hulley S., Furberg C., Barrett-Connor E., et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (2002) 58-66
5. Utian W.H. Managing menopause after HERS II and WHI: coping with the aftermath. Menopause Manage 14 (2002) 6-7
6. Hulley S.B., and Grady D. The WHI estrogen-alone trial-do things look any better?. JAMA 291 (2004) 1769-1771
7. Anderson G.L., Limacher M., Assaf A.R., and for the Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
8. Mcintosh J., and Blalock S. Effects of media coverage of women's health initiative study on attitudes and behavior of women receiving hormone replacement therapy. Am J Health Syst Pharm 62 1 (2005) 69-74
9. Shumaker S.A., Legault C., Rapp S.R., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 20 (2003) 2651-2662
10. Shumaker S.A., Legault C., Kuller L., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291 24 (2004) 2947-2958
11. Beral V., and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 362 9382 (2003) 419-427
12. Beral V., Bull D., Reeves G., et al. Endometrial cancer and hormone-replacement therapy in the million women study. Lancet 365 9470 (2005) 1543-1551
13. Faber A., Bouvy M.L., Loskamp L., et al. Dramatic change in prescribing of hormone replacement therapy in the Netherlands after publication of the million women study: a follow-up study. Br J Clin Pharmacol 60 6 (2005) 641-647
14. Chleboweki R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. JAMA 289 (2003) 3254-3263
15. Speroff L. Postmenopausal hormone therapy and the risk of breast cancer: a clinician's view. Maturitas 49 (2004) 51-57
16. Sendag F., Terek M.C., and Ozsener S. Mammographic density changes during different postmenopausal hormone replacement therapies. Fertil Steril 76 (2001) 445-450
17. US Preventive Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the US Preventive Services Task Force. Ann Intern Med 142 (2005) 855-860
18. American College of Obstetricians and Gynecologists. ACOG issues state-of-the-art guide to hormone therapy. September 30, 2004. Available at: www.acog.org/from_home/publications/press_releases/nr09-30-04-2.cfm. Accessed November 22, 2005.
19. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of the North American menopause society. Menopause 11 1 (2004) 11-33
20. The North American Menopause Society. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 11 (2004) 589-600
21. Utian W.H., Shoupe D., Bachmann G., et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 75 (2001) 1065-1079
22. Archer D.F., Dorin M., Lewis V., et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 75 (2001) 1080-1087
23. Pickar J.H., Yeh I.T., Wheeler J.E., et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 80 (2003) 1234-1240
24. US Food and Drug Administration. "Angeliq". Available at http://www.fda.gov. Accessed December 14, 2005.
25. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 275 5 (1996) 370-375
26. Modena M.G., Sismondi P., Mueck A.O., et al., The TREAT Collaborative Study Group. New evidence regarding hormone replacement therapies is urgently required: transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas 52 1 (2005) 1-10
27. Nelson H.D. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291 (2004) 1610-1620
28. Samsioe G. Transdermal hormone therapy: gels and patches. Climacteric 7 4 (2004) 347-356
29. Rioux J.E., Devlin C., Gelfand M.M., et al. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 7 3 (2000) 156-161
30. Suckling J., Lethaby A., and Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 4 (2003) CD001500
31. Mashchak C.A., Lobo R.A., Dozono-Takano R., et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 144 (1982) 511-518
32. The North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of the North American Menopause Society. Menopause 12 5 (2005) 497-511
33. Mahaday G.B., Parrot J., Lee C., et al. Botanical dietary supplement use in peri- and postmenopausal women. Menopause 10 (2003) 65
34. Boothby L.A., Doering P.L., and Kipersztok S. Bioidentical hormone therapy: a review. Menopause 11 3 (2004) 356-367
35. Pepping J. Black cohosh: Cimicifuga racemosa. Am J Health Syst Pharm 56 (1999) 1400-1402
36. Liske E., Hanggi W., Henneicke-von Zepelin H.H., et al. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizome): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Heath Gend Based Med 11 (2002) 163-174
37. American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin Clinical Management Guidelines for Obstetrician-Gynecologists. Use of botanicals for management of menopausal symptoms. Obstet Gynecol 97 Suppl (2001) 1-11
38. Taylor M. Botanicals: medicines and menopause. Clin Obstet Gynecol 44 (2001) 853-863
39. Tham D.M., Gardnes C.D., and Haskell W.L. Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 83 (1998) 2223-2225
40. Krebs E.E., Ensrud K.E., MacDonald R., et al. Phytoestrogens for treatment of menopausal symptoms: a systemic review. Obstet Gynecol 104 (2004) 824-836
41. Dog T.L. Menopause: a review of botanical dietary supplements. Am J Med 188 (2005) 98S-108S
42. Loprinzi C.L., Stearns V., and Barton D. Centrally active nonhormonal hot flash therapies. Am J Med 118 (2005) (12)(Suppl 2):118S-23S